PD-1xVEGF bispecific
Minghui Raises $131M to Advance PD-1xVEGF Bispecific Antibody Program
Minghui; Chinese biotech; PD-1xVEGF bispecific; fundraising; pre-IPO; ADC trials; JAK inhibitor; oncology; clinical development
Actionable Insights Powered by AI
Minghui; Chinese biotech; PD-1xVEGF bispecific; fundraising; pre-IPO; ADC trials; JAK inhibitor; oncology; clinical development